RemeGen Statistics

Total Valuation

RemeGen has a market cap or net worth of HKD 61.14 billion. The enterprise value is 62.66 billion.

Market Cap	61.14B
Enterprise Value	62.66B

Important Dates

The next estimated earnings date is Tuesday, October 28, 2025.

Earnings Date	Oct 28, 2025
Ex-Dividend Date	n/a

Share Statistics

RemeGen has 555.84 million shares outstanding. The number of shares has increased by 0.23% in one year.

Current Share Class	200.81M
Shares Outstanding	555.84M
Shares Change (YoY)	+0.23%
Shares Change (QoQ)	-3.92%
Owned by Insiders (%)	12.28%
Owned by Institutions (%)	58.43%
Float	464.30M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	26.91
PB Ratio	23.67
P/TBV Ratio	25.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-50.27
EV / Sales	27.59
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-72.97

Financial Position

The company has a current ratio of 1.06, with a Debt / Equity ratio of 1.13.

Current Ratio	1.06
Quick Ratio	0.74
Debt / Equity	1.13
Debt / EBITDA	n/a
Debt / FCF	-3.41
Interest Coverage	-13.16

Financial Efficiency

Return on equity (ROE) is -45.30% and return on invested capital (ROIC) is -13.42%.

Return on Equity (ROE)	-45.30%
Return on Assets (ROA)	-11.67%
Return on Invested Capital (ROIC)	-13.42%
Return on Capital Employed (ROCE)	-32.81%
Revenue Per Employee	739,940
Profits Per Employee	-405,999
Employee Count	2,999
Asset Turnover	0.36
Inventory Turnover	0.51

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +752.84% in the last 52 weeks. The beta is 0.86, so RemeGen's price volatility has been lower than the market average.

Beta (5Y)	0.86
52-Week Price Change	+752.84%
50-Day Moving Average	84.85
200-Day Moving Average	44.58
Relative Strength Index (RSI)	55.36
Average Volume (20 Days)	6,825,494

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, RemeGen had revenue of HKD 2.27 billion and -1.25 billion in losses. Loss per share was -2.31.

Revenue	2.27B
Gross Profit	1.89B
Operating Income	-1.19B
Pretax Income	-1.25B
Net Income	-1.25B
EBITDA	-918.23M
EBIT	-1.19B
Loss Per Share	-2.31

Full Income Statement

Balance Sheet

The company has 1.41 billion in cash and 2.93 billion in debt, giving a net cash position of -1.52 billion or -2.74 per share.

Cash & Cash Equivalents	1.41B
Total Debt	2.93B
Net Cash	-1.52B
Net Cash Per Share	-2.74
Equity (Book Value)	2.58B
Book Value Per Share	4.87
Working Capital	164.66M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -591.36 million and capital expenditures -267.41 million, giving a free cash flow of -858.77 million.

Operating Cash Flow	-591.36M
Capital Expenditures	-267.41M
Free Cash Flow	-858.77M
FCF Per Share	-1.55

Full Cash Flow Statement

Margins

Gross margin is 83.07%, with operating and profit margins of -52.27% and -54.87%.

Gross Margin	83.07%
Operating Margin	-52.27%
Pretax Margin	-54.87%
Profit Margin	-54.87%
EBITDA Margin	-40.42%
EBIT Margin	-52.27%
FCF Margin	n/a

Dividends & Yields

RemeGen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.23%
Shareholder Yield	n/a
Earnings Yield	-2.04%
FCF Yield	-1.40%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RemeGen has an Altman Z-Score of 1.52 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.52
Piotroski F-Score	4